COST EFFECTIVENESS STUDY OF THE RECOMBINANT COAGULATION FACTOR VIII UNITED TO PROTEIN FC FOR THE TREATMENT OF HEMOPHILIA A IN CHILE

被引：0
|
作者：
Vargas, C. [1 ]
Balmaceda, C. [1 ]
Rodriguez, F. [2 ]
Rojas, R. [1 ]
Espinoza, M. A. [3 ]
机构：
[1] Pontificia Univ Catolica Chile, Santiago, Chile
[2] Univ San Sebastian, Santiago, Chile
[3] Univ York, Ctr Econ Salud, York, N Yorkshire, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2700
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY29
引用
收藏
页码：A894 / A895
页数：2
相关论文
共 50 条
  • [1] Recombinant coagulation factor VIII Fc-von Willebrand factor fusion protein Treatment of hemophilia A
    Villarreal-Martinez, Laura
    Zamora-Martinez, Paola Lizeth
    [J]. DRUGS OF THE FUTURE, 2022, 47 (10) : 711 - 714
  • [2] Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
    Mahlangu, Johnny
    Powell, Jerry S.
    Ragni, Margaret V.
    Chowdary, Pratima
    Josephson, Neil C.
    Pabinger, Ingrid
    Hanabusa, Hideji
    Gupta, Naresh
    Kulkarni, Roshni
    Fogarty, Patrick
    Perry, David
    Shapiro, Amy
    Pasi, K. John
    Apte, Shashikant
    Nestorov, Ivan
    Jiang, Haiyan
    Li, Shuanglian
    Neelakantan, Srividya
    Cristiano, Lynda M.
    Goyal, Jaya
    Sommer, Jurg M.
    Dumont, Jennifer A.
    Dodd, Nigel
    Nugent, Karen
    Vigliani, Gloria
    Luk, Alvin
    Brennan, Aoife
    Pierce, Glenn F.
    [J]. BLOOD, 2014, 123 (03) : 317 - 325
  • [3] Cost-utility study of recombinant factor VIII in the treatment of hemophilia a in Mexico
    Soria-Cedillo, I. F.
    De la Mora-Chavez, T.
    Del Campo-Perez, M.
    Brugada-Cruces, C.
    Garcia-Contreras, F.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A162 - A162
  • [4] Cost-utility study of recombinant factor VIII in the treatment of hemophilia A in Mexico
    Garcia-Contreras, F.
    De La Mora-Chavez, T.
    Del Campo-Perez, M.
    Brugada-Cruces, C.
    Soria-Cedillo, I.
    [J]. HAEMOPHILIA, 2008, 14 : 134 - 134
  • [5] Observational study of recombinant factor VIII-Fc, rFVIIIFc, in hemophilia A
    Ebbert, Patrick T.
    Xavier, Frederico
    Malec, Lynn M.
    Seaman, Craig D.
    Ragni, Margaret, V
    [J]. THROMBOSIS RESEARCH, 2020, 195 : 51 - 54
  • [6] Recombinant factor VIII Fc (Biogen/Swedish Orphan Biovitrium) for the treatment of hemophilia A
    Eyre-Brook, Susannah N.
    Smith, Mark P.
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (10): : 1109 - 1116
  • [7] Development of a Pegylated Dimeric Recombinant Factor VIII-Fc Fusion Protein for the Treatment for Hemophilia a Patients
    Liu, Bin
    Wang, Xiaoshan
    Li, Xueqin
    Yan, Haixia
    Wang, Shuya
    Zhu, Xi
    Wang, Pengju
    Gao, Jie
    Wang, Yali
    Su, Hongsheng
    [J]. BLOOD, 2018, 132
  • [8] Clinical Use of Recombinant Factor VIII Fc and Recombinant Factor IX Fc in Patients with Hemophilia A and B
    Wang, Cassandra
    Young, Guy
    [J]. BLOOD, 2017, 130
  • [9] Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
    Powell, Jerry S.
    Josephson, Neil C.
    Quon, Doris
    Ragni, Margaret V.
    Cheng, Gregory
    Li, Ella
    Jiang, Haiyan
    Li, Lian
    Dumont, Jennifer A.
    Goyal, Jaya
    Zhang, Xin
    Sommer, Jurg
    McCue, Justin
    Barbetti, Margaret
    Luk, Alvin
    Pierce, Glenn F.
    [J]. BLOOD, 2012, 119 (13) : 3031 - 3037
  • [10] Clinical efficacy of recombinant factor VIII Fc fusion protein in hemophilia A patient receiving on demand treatment only, a cross sectional study
    Saad, Saima
    Altaf, Chaudhry
    Ahmed, Pervaiz
    Zafar, Lubna
    Iqbal, Muhammad
    Zafar, Tahira
    [J]. HAEMOPHILIA, 2018, 24 : 58 - 58
12345